Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management. Issue 5 (May 2017)

• Record Type: Journal Article
• Authors: Newbold, K.L.; Flux, G.; Wadsley, J.
• Is Part Of: Clinical oncology. Volume 29:Issue 5(2017)
• Page Start: 307
• Page End: 309
• Publication Date: 2017-05
• Subjects: Cancer -- kinase inhibitors -- re-differentiation -- thyroid; Oncology -- Periodicals; Tumors -- Periodicals; Cancer -- Treatment -- Periodicals; Radiotherapy -- Periodicals; Neoplasms -- Periodicals; Cancer -- Radiotherapy; Cancer -- Treatment; Oncology; Medical radiology; Radiotherapy; Tumors; Electronic journals; Periodicals; 616.994
• DOI: 10.1016/j.clon.2016.12.008
• Languages: English
• ISSNs: 0936-6555

Abstract

Abstract: The management of early stage differentiated thyroid cancer (DTC) with low risk of recurrence has been the subject of much interest and investigation in the recent years. Locally advanced DTC and patients with a high risk of recurrent disease however needs further investigation. This short review will look at what constitutes high risk thyroid cancer, the definition of radioiodine refractory disease, the current management and areas of debate within this clinical setting.